Loading
In the first human study of imatinib, almost every patient with chronic-phase CML who had failed interferon regained normal blood counts, with mild side effects.
Phase 1 dose-escalation study of the ABL kinase inhibitor STI571 (imatinib) in 83 patients with chronic-phase CML in whom interferon alfa had failed. Doses of 25 to 1000 mg daily were tested and no maximum tolerated dose was reached. At 300 mg or more, complete haematological responses occurred in 53 of 54 patients, usually within four weeks, and cytogenetic responses in 29 of 54 (17 major). It was the first demonstration that a small molecule designed against a defined oncogenic kinase could control a human cancer, and became the template for targeted therapy.
Druker's 2001 imatinib paper turned the idea of hitting a cancer's specific molecular engine into a working medicine. For people with CML it began the shift from a fatal disease treated with interferon or transplant to one managed with a daily tablet. It also set expectations, later tempered, that every cancer might have its own imatinib.
Shares IRIS: imatinib versus interferon plus cytarabine as first treatment for chronic myeloid leukaemia, Chronic myeloid leukaemia (CML), Imatinib.
Shares Chronic myeloid leukaemia, chronic phase, Chronic myeloid leukaemia (CML), Imatinib, Novartis.
Shares Chronic myeloid leukaemia, chronic phase, Chronic myeloid leukaemia (CML), Novartis.
Shares Chronic myeloid leukaemia, chronic phase, Chronic myeloid leukaemia (CML), Novartis.
Shares Chronic myeloid leukaemia, chronic phase, Chronic myeloid leukaemia (CML), Novartis.
Shares Chronic myeloid leukaemia, chronic phase, Chronic myeloid leukaemia (CML), Imatinib.
Shares BCR::ABL1 (Philadelphia chromosome), Chronic myeloid leukaemia (CML), The valley of death between lab and product, Imatinib.
Shares Chronic myeloid leukaemia, chronic phase, Chronic myeloid leukaemia (CML), Novartis.